文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Epidemiology, clinical treatment patterns, and survival of hepatocellular carcinoma in Manitoba.

作者信息

Hanumanthappa Nikesh, Cho Byung Heon, McKay Andrew, Peretz David, Y Minuk Gerald, Lambert Pascal, Nashed Maged

机构信息

Department of Radiation Oncology, CancerCare Manitoba, University of Manitoba, Winnipeg, Manitoba, Canada.

Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.

出版信息

Can Liver J. 2020 Jun 4;3(2):194-202. doi: 10.3138/canlivj.2019-0015. eCollection 2020 Spring.


DOI:10.3138/canlivj.2019-0015
PMID:35991857
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9202782/
Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) has a very poor survival rate, especially for those who do not receive a potentially curative therapy. METHODS: Treatment details were collected for 320 HCC patients diagnosed in Manitoba between January 2011 and December 2015. Patients had a mean age of 67.3 years, and 71.6% were men. Of these patients, 67 (20.9%) received curative treatment, 36 (11.3%) received non-curative treatment, and 217 (67.8%) received supportive care only; 71.3% of patients had liver cirrhosis. Alcoholic cirrhosis was the most common etiology of chronic liver disease (22.2%). RESULTS: Those who received curative treatment had a significantly lower incidence of portal vein thrombosis and multinodular disease than those in other groups. Patients who received supportive care only had a higher incidence of ascites. We found no difference in the distribution of cirrhosis or portal hypertension among the treatment groups. The 2- and 5-year overall survival rates for the whole cohort were 27% and 14%, respectively. No significant change was found in 2-year survival for patients diagnosed in each year from 2011 to 2015 ( = 0.250). Also, we found no significant change in proportion of treatment given to patients over the same period ( = 0.432). CONCLUSION: The poor survival rate of HCC patients in Manitoba could potentially be improved by maximizing the use of local therapy and by implementing multidisciplinary-based case discussion. Efforts should also be directed toward early management of infective, alcoholic, and non-alcoholic steatohepatitis, which will, we hope, lead to a reduction in the incidence of HCC.

摘要

相似文献

[1]
Epidemiology, clinical treatment patterns, and survival of hepatocellular carcinoma in Manitoba.

Can Liver J. 2020-6-4

[2]
[Effect of splenectomy on the risk of hepatocellular carcinoma development among patients with liver cirrhosis and portal hypertension: a multi-institutional cohort study].

Zhonghua Wai Ke Za Zhi. 2021-10-1

[3]
Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis.

J Hepatol. 2018-8-6

[4]
Investigating the risk factors of hepatocellular carcinoma and survival analysis for cirrhosis after transjugular intrahepatic portosystemic shunt in treating portal hypertension.

J Cancer Res Ther. 2018

[5]
Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma.

Clin Mol Hepatol. 2020-4

[6]
Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease.

Aliment Pharmacol Ther. 2017-12

[7]
A study of 3013 cases of hepatocellular carcinoma: Etiology and therapy before and during the current decade.

JGH Open. 2021-7-27

[8]
Temporal trends in disease presentation and survival of patients with hepatocellular carcinoma: A real-world experience from 1998 to 2015.

Cancer. 2018-4-6

[9]
Improving survival in patients with hepatocellular carcinoma related to chronic hepatitis C and B but not in those related to non-alcoholic steatohepatitis or alcoholic liver disease: a 20-year experience from a national programme.

Intern Med J. 2019-11

[10]
Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease.

World J Gastroenterol. 2016-10-7

引用本文的文献

[1]
Real-World Treatment Patterns, Clinical Outcomes, Healthcare Resource Utilization, and Costs in Advanced Hepatocellular Carcinoma in Ontario, Canada.

Cancers (Basel). 2024-6-15

[2]
Treatment journey of patients with hepatocellular carcinoma using real-world data in British Columbia, Canada.

Hepat Oncol. 2024-3-14

[3]
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.

Nat Rev Gastroenterol Hepatol. 2021-4

本文引用的文献

[1]
Disease Burden of Hepatocellular Carcinoma: A Global Perspective.

Dig Dis Sci. 2019-4

[2]
Radiotherapy for Hepatocellular Carcinoma Results in Comparable Survival to Radiofrequency Ablation: A Propensity Score Analysis.

Hepatology. 2019-5-2

[3]
Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients.

PLoS One. 2019-1-14

[4]
Staging systems of hepatocellular carcinoma: A review.

Indian J Gastroenterol. 2018-11

[5]
Epidemiology and Management of Hepatocellular Carcinoma.

Gastroenterology. 2018-10-24

[6]
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

CA Cancer J Clin. 2018-9-12

[7]
Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis.

Gastroenterology. 2018-2-6

[8]
The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines from 2001 to 2017.

Biosci Trends. 2017

[9]
AASLD guidelines for the treatment of hepatocellular carcinoma.

Hepatology. 2018-1

[10]
Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012.

Gastroenterology. 2017-3

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索